alexa Clinical Use Of Ponatinib In Mixed Lineage Acute Leukaemia Associated With T 8:22 | Open Access Journals
ISSN: 2329-6917
Journal of Leukemia
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Clinical Use Of Ponatinib In Mixed Lineage Acute Leukaemia Associated With T 8:22

David Paul Busuttil*

Consultant Haematologist, Mater Dei Hospital, Malta, UK

*Corresponding Author:
Dr. David Paul Busuttil, MD MSc FRCP FRCPath
Consultant Haematologist, Mater Dei Hospital, Malta, UK
Tel: 21313692, 25456348
E-mail: [email protected]

Received date: July 16, 2015 Accepted date: August 05, 2015 Published date: August 12, 2015

Citation: Busuttil DP (2015) Clinical Use Of Ponatinib In Mixed Lineage Acute Leukaemia Associated With T 8:22. J Leuk (Los Angel) S1:004. doi: 10.4172/2329-6917.S1-004

Copyright: © 2015 Busuttil DP, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Leukemia

Letter to the Editor

The 8p11 myeloproliferative syndrome (EMS) is a rare and aggressive haematological neoplasm caused by rearrangements involving fibroblast growth factor receptor 1 (FGFR1) gene on chromosome 8p11. Involvement of t 8:22/ BCR-FGFR1 is extremely rare and presents as a chronic myeloid leukaemia – like disease rapidly evolving into acute leukaemia [1,2]. The cell origin of EMS is a very early progenitor cell retaining the potential for both myeloid and lymphoid differentiation. The prognosis is poor and there are no documented cases of complete remission after conventional chemotherapy. A number of FGFR1 inhibitors have shown promising in vitro activity in this condition but none have shown significant clinical responses [3,4]. Ponatinib, a potent pan – FGFR1 inhibitor has shown potent in vitro activity and is clinically available [5].

I present the case of a 48 year old lady who presented with an abnormal blood count WBC 75 × 109 /l Hb 10.5 g/l Platelets 9 × 109 /l. The blood film looked like blastic phase CML with 20% blasts, left shifted neutrophilia and basophilia. Examination of 16 metaphases revealed t 8:22. Flow cytometry showed two blast cell populations of myeloblasts (6.6%) and CD 20 negative lymphoblasts (13%). She was induced with hyperCVAD/MA resulting in clearance of blasts from the marrow aspirate. A second inductio with FLAG/Ida was carried out and she went on to receive two further cycles of FLAG. Immunologically, the lymphoblasts were cleared but the myeloblasts persisted at low but stable levels and she eventually developed overt acute myeloid leukaemia. It was at this stage that ponatinib was introduced with the aim of achieving a remission period long enough for her to undergo a sibling allogeneic transplant. However there was no response and she died of progressive disease.

This case demonstrates the biphenotypic nature of the leukaemia associated with t8:22. It also documents the failure of clinical activity of ponatinib. Although stem cell transplantation is the only curative option, in almost all cases there is a failure to attain a durable remission with both conventional chemotherapy, PDGF1 inhibitors and tyrosine kinase inhibitors even when these are used in combination.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11686
  • [From(publication date):
    specialissue-2015 - Oct 24, 2017]
  • Breakdown by view type
  • HTML page views : 7909
  • PDF downloads :3777
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords